Department of Internal Medicine, Cancer Research Institute, and College of Medicine, Chungnam National University, Daejeon, Korea.
Histol Histopathol. 2012 Sep;27(9):1155-61. doi: 10.14670/HH-27.1155.
Gastric cancer is the second leading cause of cancer deaths worldwide. Despite the extensive body of research on gastric cancer, the prognosis of patients with advanced gastric cancer remains poor, and therapy for advanced gastric cancer relies largely on cytotoxic chemotherapy. Therefore, identifying the distinct molecular pathways underlying disease progression and treatment resistance may lead to novel therapeutic approaches, as well as improve the quality of life and survival of patients. The chemokine CXCL12 and its receptor CXCR4 are now known to play an important role in cancer development and progression. Here, we review the expression and function of CXCR4 and CXCL12, as well as their clinical relevance in gastric cancer. We also cover the current molecular mechanism, specifically the cell-signaling pathway, by which gastric cancer progresses through the CXCR4/CXCL12 axis, and discuss the potential of that axis as a therapeutic target in the treatment of gastric cancer.
胃癌是全球癌症死亡的第二大主要原因。尽管有大量关于胃癌的研究，但晚期胃癌患者的预后仍然很差，晚期胃癌的治疗主要依赖细胞毒性化疗。因此，确定疾病进展和治疗耐药性的独特分子途径可能会导致新的治疗方法，并提高患者的生活质量和生存率。趋化因子 CXCL12 及其受体 CXCR4 现在已知在癌症的发展和进展中发挥重要作用。在这里，我们回顾了 CXCR4 和 CXCL12 的表达和功能，以及它们在胃癌中的临床相关性。我们还介绍了目前通过 CXCR4/CXCL12 轴使胃癌进展的分子机制，特别是细胞信号通路，并讨论了该轴作为治疗胃癌的治疗靶点的潜力。
